Compare VSTS & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSTS | RCKT |
|---|---|---|
| Founded | 1936 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 572.2M | 340.9M |
| IPO Year | N/A | N/A |
| Metric | VSTS | RCKT |
|---|---|---|
| Price | $7.59 | $3.41 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $5.95 | ★ $29.12 |
| AVG Volume (30 Days) | ★ 3.2M | 2.3M |
| Earning Date | 01-30-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,734,839,000.00 | N/A |
| Revenue This Year | $1.47 | N/A |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.98 | $2.19 |
| 52 Week High | $16.68 | $13.50 |
| Indicator | VSTS | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 75.53 | 52.07 |
| Support Level | $7.10 | $3.30 |
| Resistance Level | $7.71 | $3.65 |
| Average True Range (ATR) | 0.40 | 0.19 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 95.44 | 66.22 |
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.